Entero Therapeutics transitions COO Jack Syage to Chief Scientific Officer

GridAI Technologies Corp.

Jack Syage, previously President and COO, appointed Chief Scientific Officer effective June 17, 2024.
Syage retains President title and reports to CEO James Sapirstein; compensation unchanged.
Chief Operating Officer role vacated; no replacement named.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jack Syage

Chief Scientific Officer

GRDX · GridAI Technologies Corp.

Effective: 2024-06-17
Filed: June 20, 2024, 7:59 PM ET

transitioned Dr. Syage from the role of Chief Operating Officer to the newly appointed role of Chief Scientific Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jack Syage changed role as Chief Scientific Officer at GridAI Technologies Corp..

Action: transitioned
Role: Chief Scientific Officer

Exact text from the filing

transitioned Dr. Syage from the role of Chief Operating Officer to the newly appointed role of Chief Scientific Officer, effective immediately.

View on SEC.gov

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001104659-24-073418

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.